AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04453644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle static stretching
Description: On day-I: Static Stretching done for 2 minutes (SS2), on day-II: Static Stretching done for 4 minutes (SS4), and on day-III: Static Stretching done for 8 minutes (SS8).
Study NCT01237470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Desarda technique
Description: no mesh technique with undetached strip of external oblique aponeurosis placed at the floor of inguinal canal
Study NCT01237470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lichtenstein technique
Description: hernioplasty with the usage of plain polypropylene mesh
Study NCT03789409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: The aforementioned intermittent fasting in arm/group descriptions.
Study NCT02986451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.
Study NCT00611156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ginger
Description: added to a brunch meal
Study NCT00611156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: black pepper
Description: Added to a brunch meal
Study NCT00611156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: horseradish
Description: Added to a brunch meal
Study NCT00611156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mustard
Description: Added to a brunch meal
Study NCT02986451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle
Study NCT00597805 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires/interviews
Description: All patients who agree to participate will be interviewed for a baseline quality of life assessment prior to surgery. A brief in hospital interview will follow in the peri-operative period. In the ensuing months, patients will be interviewed at approximately 3, 6 and 12 months post-operatively (eg: 3 month interview will be done between 8-16 weeks and 6 month interview between 20-28 months post-operatively). Annual interviews in years two through five will be employed to determine areas for future study and solicit narrative on transition toward cancer survivorship.
Study NCT03322267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Cisplatin (30 mg/m2, QW, 2 cycles) and radiotherapy (18-26 Gy/10-13 fractions) as adjuvant chemoradiotherapy, followed by pembrolizumab (200mg, Q3W, 18 cycles)
Study NCT03877939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples collection for analysis
Description: Blood samples:~Blood samples will be collected for the determination of the levels of various biomarkers (Kisspeptins and miRNAs), which are molecules that regulate the expression of proteins and can serve as markers for predicting pregnancy viability. Additionally, after biochemical or week 10 of clinical pregnancy confirmation, blood samples will be collected for KIR and HLA-C typing, Oral glucose tolerance test (OGTT) and analysis of the levels of miRNAs related with insulin resistance, miR-424-5p and miR-15b.~Uterine biopsy (only in patients with BP):~Uterine biopsy samples will be collected also after biochemical pregnancy confirmation for the determination of the levels of miRNAs related with insulin resistance, miR-424-5p and miR-15b.
Study NCT03651739 — intervention group
Intervention type: DEVICE
Intervention: Knee Connect
Description: An electronic goniometer with smart phone application
Study NCT01756326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PREOB® Implantation
Study NCT01756326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Autograft
Study NCT03927300 — intervention group
Intervention type: DEVICE
Intervention: Telemonitoring Software
Description: Recovery of retrospective data in dialysis patients follow or not follow by a telemonitoring application.
Study NCT00859105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5%: manufactured by Apotex
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, 16 weeks
Study NCT00859105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adara 5% Cream US
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
Study NCT00859105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adara 5% Cream Canada
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks.
Study NCT00859105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Imiquimod Vehicle
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
Study NCT02486081 — intervention group
Intervention type: DEVICE
Intervention: smart soccer ball
Description: smart soccer ball was used to measure participant's performance in total time and distance for completion, and acceleration
Study NCT04215705 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus block versus peritubal local infiltration
Description: Quadratus lumborum block III versus peritubal local infiltration in patients undergoing Percutaneous Nephrolithotomy operation
Study NCT00777023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Extended-Release (G-ER) 1200 mg
Description: G-ER 1200 mg daily dosage given as two 600-mg tablets.
Study NCT00777023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Extended-Release (G-ER) 1800 mg
Description: G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
Study NCT00777023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
Study NCT00085293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Starting dose 6 mg/m\^2 intravenously over 1 hour every day for 5 successive days for 2 weeks (10 doses), with possible second course.
Study NCT00085293 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iodine I 131
Description: Undergo thyrotropin-alfa stimulated radioactive iodine scan
Study NCT00085293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant thyrotropin alfa
Description: Undergo thyrotropin-alfa stimulated radioactive iodine scan
Study NCT00085293 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F 18
Description: Optional correlative studies
Study NCT00085293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography
Description: Optional correlative studies
Study NCT01180634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aeroquin
Description: Inhalation Solution
Study NCT01180634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation Solution
Study NCT01564394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Classes will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. The classes will be led by a trained Qigong instructor and consist of postures, movements, deep breathing techniques and meditation. It will include eccentrically-biased Qigong movements with an emphasis on weight shifting and posture control. The continuous body movements coupled with progressively diminishing base of support, dynamic challenge to balance, and concentration on body positions requiring eccentric muscle activity should improve the levels of fatigue and quality of life in older prostate cancer survivors.
Study NCT01564394 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Non-aerobic stretching
Description: The non-aerobic stretching classes will serve as an attention control. They will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. They will be led by an Huntsman Cancer Institute (HCI) fitness specialist and will consist of light stretching exercises; while avoiding a focus on meditation.
Study NCT01441297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: BIBF 1120 200mg bid, PO, daily until PD
Study NCT02901379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg
Description: Subject will be given atorvastatin 80mg for two weeks
Study NCT02901379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Subjects will be give atorvastatin 10mg as part of standard therapy in hospital
Study NCT04304066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-WL12 PET or 68Ga-WL12 PET
Description: WL12, labeled with PET radio-nuclide ( Ga-68 or F-18)will be used as a molecular imaging tracer for PET/CT scanning
Study NCT03505151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306 (C-13/N-15)
Description: i.v solution
Study NCT03505151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet
Study NCT02986451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle.
Study NCT03190239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg qd
Study NCT03190239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m2 qm
Study NCT02199873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIX 1 XX - single rising dose
Study NCT02199873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01098968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: School intervention program specifically designed to increase health-related physical fitness
Study NCT00686751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: Dosage Form: Intravenous administration. Dosage: 0.01 micrograms/kilogram of body weight. Frequency: 2 HD treatments of each study week (depending on phase of study). Duration: 4 weeks.
Study NCT06673420 — intervention group
Intervention type: OTHER
Intervention: No Interventions
Description: This is an observational study
Study NCT00572143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ca coli follow-up by GP
Description: patients randomized to follow up by GP
Study NCT02038374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsies
Study NCT04603378 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: KB195
Description: KB195 is a novel glycan
Study NCT04603378 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Polydextrose
Description: Polydextrose is an oligosaccharide
Study NCT04603378 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pullulan
Description: Pullulan is an oligosaccharide
Study NCT04603378 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Maltodextrin
Description: Maltodextrin is a digestible carbohydrate
Study NCT02604121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orcellex® Rovers brush
Description: transepithelial brushing
Study NCT03690960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrospun TAP nanofibers
Description: electrospun TAP loaded nanofibers containing modified triple antibiotic paste of clindamycin , ciprofloxacin and metronidazole by electrospinning process will be placed in the root canals. The access cavity will be sealed with temporary filling material
Study NCT03690960 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified TAP paste
Description: modified TAP paste will be prepared by mixing equal proportions of CIP, MET and CLIN then placed inside the root canal, access cavity will be sealed with temporary filling
Study NCT04066088 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered same times as GXR
Study NCT04066088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR)
Description: The starting dose for all subjects will be 1 mg per day. If the medication is well-tolerated, the dose can be raised to 2 mg until day 28 and increased to 3mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed; the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8, the study will be unblinded and subjects will continue treatment for 8 more weeks.
Study NCT01773408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5503781 MBP
Description: Participants will receive RO5503781 tablets daily (current formulation) containing microprecipitated bulk powder (MBP) at a starting dose of 400 milligrams (mg).
Study NCT00611156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Added to a bruch meal
Study NCT01773408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5503781 SDP
Description: Participants will receive RO5503781 tablets daily (new optimized formulation) containing spray-dried powder (SDP) at recommended dose(s) for development from Phase 1b to Phase 3.
Study NCT01773408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Idarubicin will be administered as per standard clinical practice.
Study NCT01773408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Daunorubicin will be administered as per standard clinical practice.
Study NCT01773408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Parts 2 and 4: Participants will receive cytarabine 1000 milligrams per meter squared (mg/m\^2) intravenous (IV) infusion daily. Part 3: Participants will receive cytarabine 100-200 mg/m\^2 IV infusion daily.
Study NCT02057835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 691751
Description: Placebo to BI 691751
Study NCT02057835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751 high dose
Description: BI 691751 high dose
Study NCT02057835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751 middle dose
Description: BI 691751 middle dose
Study NCT03474835 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ISCHEMIC HEART DISEASE diagnostic
Description: ISCHEMIC HEART DISEASE diagnostic
Study NCT01535300 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasonography of the trachea
Description: Ultrasonographic measurement of the minimal transverse tracheal diameter
Study NCT03475953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1 : Regorafenib
Description: A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Patients will be allocated 3 dose levels of Regorafenib following a 3 + 3 design.
Study NCT03475953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1 : Avelumab
Description: A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Avelumab will be administered on cycle 1 Day 15 as a 1-hour intravenous (IV) infusion (10mg/kg), repeated every two weeks thereafter (ie. Day 1 and Day 15 of each subsequent cycle, as a 1-hour intravenous infusion).
Study NCT03475953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2 : Regorafenib
Description: Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.
Study NCT03475953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2 : Avelumab
Description: Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.
Study NCT03475953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2: low-dose Regorafenib
Description: Phase 2 : Regorafenib - All patients will be treated at a fixed low-dose of regorafenib of 80 mg/day
Study NCT00130442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI-88 and dacarbazine
Description: 190 mg daily by subcutaneous injection for PI-88 and 1000 mg/m2 on day 1 of each 21 day cycle by intravenous infusion
Study NCT00130442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine or DTIC
Description: intravenous infusion 1000 mg/m2 on day 1 of every 21 day cycle
Study NCT02112448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous infusion
Description: Continuous morphine/midazolam and 'as needed' doses. Will receive scheduled acetaminophen and ketorolac.
Study NCT02112448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: as needed dosing
Description: morphine and midazolam as needed. Will receive scheduled acetaminophen and ketorolac..
Study NCT02112448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen will be given every 4 hours for a total of 24 hours.
Study NCT02112448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketorolac
Description: Ketorolac 0.5 mg/kg will be given every six hours to all subjects in the study.
Study NCT04486274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MOSE
Description: After each pass, the stylet will be introduced into the needle, the material will be released onto a smear slide, and a macroscopic on-site quality evaluation (MOSE) of the specimen will be performed by the endoscopist.
Study NCT00828373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the Placebo group this will be physiologic saline. The infusion will be stopped after complete recovery from the neuromuscular block.
Study NCT00828373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the lidocaine Arm this regimen corresponds to 1.5 mg kg-1 lidocaine bolus injection and 2 mg kg-1 h-1 lidocaine continuous infusion. The infusion will be stopped after complete recovery from the neuromuscular block.
Study NCT03545516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Injection of bupivacaine into the surgical incision prior to its closure.
Study NCT03545516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Injection of dexmedetomidine ( an adjuvant) into the surgical incision prior to its closure.
Study NCT03545516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of a placebo into the surgical wound
Study NCT04086043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Denervation
Description: multi-electrode catheter-based endovascular denervation
Study NCT01434225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
Study NCT01252966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: The computerized cognitive training intervention is a 12-week standardized course of internet-based computerized cognitive exercises designed to enhance executive cognitive function.
Study NCT01252966 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control training
Description: The computerized control training intervention is a 12-week standardized course of internet-based deep breathing exercises which does not contain the cognitive exercises designed to enhance executive cognitive function.
Study NCT01733706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No nicotine electronic cigarette
Description: The e-cigarette T-FUMOTM is a no nicotine electronic cigarette specifically designed to inactivate the early effects of the cessation of cigarette smoking, such as the craving caused by psychological reasons. It's formed by a filter which contains distilled water and food flavorings, an atomizer and a battery. On the opposite end to the filter there is a diode that lights up during aspiration. During the suction is generated hot air which, in contact with the liquid of the filter, generates steam which simulates the smoke of a traditional cigarette. The smoker has the sensation of smoking, but he does not suck the carcinogenic substances in traditional cigarettes and he does not assimilate nicotine.
Study NCT01733706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard counseling
Description: standard counseling
Study NCT01733706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard counseling
Description: standard counseling